|
|
Blood, 15 January 2005, Vol. 105, No. 2, pp. 496-502.
Prepublished online as a Blood First Edition Paper on September 9, 2004; DOI 10.1182/blood-2004-05-1982.
 Previous Article | Table of Contents | Next Article 
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology
Upendra Hegde,
Armando Filie,
Richard F. Little,
John E. Janik,
Nicole Grant,
Seth M. Steinberg,
Kieron Dunleavy,
Elaine S. Jaffe,
Andrea Abati,
Maryalice Stetler-Stevenson, and
Wyndham H. Wilson
From the Center for Cancer Research (CCR), National Cancer Institute (NCI), National Institutes of Health, Bethesda, MD.
We assessed the cerebrospinal fluid (CSF) by flow cytometry and cytology in 51 newly diagnosed and 9 treated aggressive B-cell lymphomas at risk for central nervous system (CNS) involvement to examine the utility of flow cytometry, incidence of CSF disease, and clinical surrogates of CNS spread. Multicolor flow cytometry using multiple antibody panels for light chains and B- and T-cell antigens identified neoplastic clones that constituted as little as 0.2% of total CSF lymphocytes. Among 51 newly diagnosed patients, 11 (22%) had occult CSF involvement. All 11 were detected by flow cytometry but only 1 by cytology (P = .002). Among 9 treated patients, CSF involvement was detected by flow cytometry alone in 2 and also by cytology in 1 case. CSF chemistry and cell counts were similar in patients with and without CSF lymphoma. Only the number of extranodal sites was associated with occult CSF lymphoma in newly diagnosed patients by univariate (P = .006) or logistic regression analysis (P = .012). We hypothesize that the biologic phenotype associated with colonization of extranodal sites leads to CNS spread, possibly related to the microenvironment. Patients at risk for CNS spread should undergo staging CSF evaluation by flow cytometry.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Occult leptomeningeal NHL: go with the flow?
- Ariela Noy
Blood 2005 105: 434.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Quijano, A. Lopez, J. Manuel Sancho, C. Panizo, G. Deben, C. Castilla, J. Antonio Garcia-Vela, A. Salar, N. Alonso-Vence, E. Gonzalez-Barca, et al.
Identification of Leptomeningeal Disease in Aggressive B-Cell Non-Hodgkin's Lymphoma: Improved Sensitivity of Flow Cytometry
J. Clin. Oncol.,
March 20, 2009;
27(9):
1462 - 1469.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. H. Bernstein, J. M. Unger, M. LeBlanc, J. Friedberg, T. P. Miller, and R. I. Fisher
Natural History of CNS Relapse in Patients With Aggressive Non-Hodgkin's Lymphoma: A 20-Year Follow-Up Analysis of SWOG 8516--The Southwest Oncology Group
J. Clin. Oncol.,
January 1, 2009;
27(1):
114 - 119.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. D. Doolittle, L. E. Abrey, T. N. Shenkier, S. Tali, J. E.C. Bromberg, E. A. Neuwelt, C. Soussain, K. Jahnke, P. Johnston, G. Illerhaus, et al.
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
Blood,
February 1, 2008;
111(3):
1085 - 1093.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M Bjorkholm, H Hagberg, H Holte, S Kvaloy, L Teerenhovi, H Anderson, E Cavallin-Stahl, J Myhre, H Pertovaara, A Ost, et al.
Central nervous system occurrence in elderly patients with aggressive lymphoma and a long-term follow-up
Ann. Onc.,
June 1, 2007;
18(6):
1085 - 1089.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.E.C. Bromberg, D. A. Breems, J. Kraan, G. Bikker, B. van der Holt, P. S. Smitt, M. J. van den Bent, M. van't Veer, and J. W. Gratama
CSF flow cytometry greatly improves diagnostic accuracy in CNS hematologic malignancies
Neurology,
May 15, 2007;
68(20):
1674 - 1679.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V Boehme, S Zeynalova, M Kloess, M Loeffler, U Kaiser, M Pfreundschuh, and N Schmitz
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
Ann. Onc.,
January 1, 2007;
18(1):
149 - 157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Anaclerico, V. Bongarzoni, A. Chierichini, M. Bartolini, P. Iacovino, S. Fenu, P. Anticoli-Borza, and L. Annino
Liposomal Cytarabine in the Central Nervous System (CNS) Prophylaxis of Elderly Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) and Undifferentiated Acute Leukemia (UAL): Preliminary Results of a Single-Center Experience.
Blood (ASH Annual Meeting Abstracts),
November 16, 2006;
108(11):
4663 - 4663.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. E. Abrey, T. T. Batchelor, A. J.M. Ferreri, M. Gospodarowicz, E. J. Pulczynski, E. Zucca, J. R. Smith, A. Korfel, C. Soussain, L. M. DeAngelis, et al.
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
J. Clin. Oncol.,
August 1, 2005;
23(22):
5034 - 5043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
